SOLICITATION NOTICE
99 -- Pharmaceuticals for the Centers for Disease Control and Prevention Clinics - Combined Synopsis/Solicitation
- Notice Date
- 1/7/2013
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2012-Q-15347
- Archive Date
- 2/5/2013
- Point of Contact
- Germaine M. Mullins, Phone: 7704881938
- E-Mail Address
-
gmullins@cdc.gov
(gmullins@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Combined Synopsis/Solicitation The Centers for Disease Control and Prevention (CDC) intends to purchase the items listed below. The Government intends to evaluate offers and award a contract without discussions with Offerors providing the requested supplies. The Government is requesting Federal Supply Schedule (FSS) pricing or Big 4 pricing. Therefore, the initial offer should contain the offeror's best terms from a technical and price standpoint. The North American Industry Classification System (NAICS) code is 325412 for this requirement. Interested vendors capable of furnishing the government with the requested service listed in the attachments for this synopsis should submit a quotation to the email address listed below. The quotation shall include the itemized price, prompt payment terms, the F.O.B. Point (Destination or Origin), Taxpayer Identification Number (TIN), Dun & Bradstreet Number (DUNs), and descriptive literature of the product quoted. The Request for Quotation Number 2013-Q-15347. The offeror must be able to provide all of the requested items listed below for a 12 month Base period and three (3) 12-month Option Periods: ITEM SUPPLIES / SERVICES QTY / UNIT 0001 Adacel NDC: 49281-0400-15 NDC: 49281-400-15 58 EA 0002 Adacel NDC: 49281-0400-10 NDC: 49281-0400-10 21 EA 0003 IPOL 10x1 Dose, Syringe NDC: 49281-860-10 15 Vials 0004 Menactra Vaccine, 5 Syringe Dose Vials NDC: 49281-589-05 40 EA 0005 Menomune ACYW135 Vaccine 1 Dose TP NDC: 49281-489-01 35 EA 0006 Decevac Generic Name: Diphtheria Toxoid/Tetanus Toxoid Adsorbed (Adult) Inj NDC: 49281-291-83 5 Pack 0007 Tubersol NDC: 49281-752-21 Generic Name: Tuberculin, Purified Protein Derivative Sunt/0.1ML Inj 175 Vials 0008 Typhim Vi Vaccine, 1 Dose Syringe NDC: 49281-790-51 Generic Name: Typhoid VI Polysaccharide (Typhim VI) Vaccine, Syringe, 0.5ML 400 Doses 0009 Typhim Vi Vaccine, Multi-dose (20) Vials NDC: 49281-790-20 Generic Name: Typhoid VI Polysaccharide (Typhim VI) Vaccine, 13 EA 0010 Yellow Fever Vaccine S/G 5X1D NDC: 49281-915-01 Yellow Fever (YF-VAX-5XIDS) Generic Name: Yellow Fever Vaccine Inj 40 Pack 0011 Tenivac NDC: 49281-215-10 10x1 Vial AD (Adult) 10 EA Quotations will be due fourteen (14) calendar days from the publication date of this synopsis or Monday, January 21, 2013, by 2:00 p.m. E.S.T. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency. Quotations must be submitted via electronic mail to: gmullins@cdc.gov. The resultant contract will be a Firm Fixed Price for a base period (12 months) and three (3) 12-month option periods. THIS IS A COMBINED SYNOPSIS/SOLICITATION FOR COMMERCIAL ITEMS PREPARED IN ACCORDANCE WITH THE FORMAT IN SUBPART 12.6, AS SUPPLEMENTED WITH ADDITIONAL INFORMATION INCLUDED IN THIS NOTICE. THIS ANNOUNCEMENT CONSTITUTES THE ONLY SOLICITATION; QUOTATIONS ARE BEING REQUESTED AND A WRITTEN SOLICITATION WILL NOT BE ISSUED. The following provisions apply to this acquisition; 52.212 1 Instructions to Offerors Commercials Items (FEB 2012) applies to this acquisition; 52.212 2, Evaluation Commercial Items (JAN 1999); the evaluation criteria stated in paragraph (a) of this provision are as follows: (1) technical capability of the proposed system to meet the requirements stated herein, and (2) price. The clause 52.212 4, Contract Terms & Conditions Commercial Items (FEB 2012) applies to this acquisition. The following FAR Clauses are hereby added to this clause: 52.247 35 F.O.B. Destination; The clause at 52.212 5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (NOV 2012) applies to this acquisition. The following clauses listed in paragraph (b) of 52.212 5 (NOV 2012) apply to this acquisition: (1), (3), (5), (7), (9), (11), (12), (14), (15), (17), (18), (20) and (24). OFFERORS SHALL INCLUDE A COMPLETED COPY OF THE PROVISION AT 52.212 3, OFFERORS REPRESENTATIONS AND CERTIFICATIONS COMMERCIAL ITEMS (DEC 2012), WITH YOUR QUOTE. An offeror shall complete only paragraph (b) of 52.212-3 provision if the offeror has completed the annual representations and certifications electronically at http://orca.bpn.gov. If an offeror has not completed the annual representations and certifications electronically at the ORCA website, the offeror shall complete only paragraphs (c) through (o) of 52.212-3 provision. Quotes will be due Monday, January 21, 2013, by 2:00 p.m. E.S.T. to Attn: Germaine Mullins to email address gmullins@cdc.gov. EMAIL INQUIRIES ONLY!!! RFQ# 2013-Q-15347.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2012-Q-15347/listing.html)
- Place of Performance
- Address: Atlanta, Georgia, United States
- Record
- SN02959970-W 20130109/130107233841-636b94a4e21887c65d79dd1ee9c6c42d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |